Luca Paoluzzi

1.4k total citations
41 papers, 1.0k citations indexed

About

Luca Paoluzzi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luca Paoluzzi has authored 41 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luca Paoluzzi's work include Cancer therapeutics and mechanisms (8 papers), Sarcoma Diagnosis and Treatment (6 papers) and Ubiquitin and proteasome pathways (6 papers). Luca Paoluzzi is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Sarcoma Diagnosis and Treatment (6 papers) and Ubiquitin and proteasome pathways (6 papers). Luca Paoluzzi collaborates with scholars based in United States, Italy and Australia. Luca Paoluzzi's co-authors include Owen A. O’Connor, Robert G. Maki, Luigi Scotto, Enrica Marchi, Munir Ghesani, Gerald Rosen, Adrienne Cacavio, Amy Rapkiewicz, Venkatraman Seshan and Romano Danesi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Luca Paoluzzi

41 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luca Paoluzzi United States 16 505 478 231 218 134 41 1.0k
Lai‐Fa Sheu Taiwan 21 439 0.9× 330 0.7× 118 0.5× 226 1.0× 136 1.0× 44 1.1k
Sheeja T. Pullarkat United States 13 234 0.5× 508 1.1× 122 0.5× 272 1.2× 179 1.3× 43 980
Vijay Peddareddigari United States 11 714 1.4× 600 1.3× 183 0.8× 127 0.6× 111 0.8× 18 1.2k
Miyuki Akutsu Japan 18 622 1.2× 516 1.1× 157 0.7× 150 0.7× 62 0.5× 40 1.2k
L. Austin Doyle United States 12 338 0.7× 407 0.9× 200 0.9× 247 1.1× 69 0.5× 35 922
Rodney R. Miles United States 19 613 1.2× 491 1.0× 84 0.4× 460 2.1× 139 1.0× 68 1.4k
Masafumi Takimoto Japan 13 213 0.4× 402 0.8× 171 0.7× 156 0.7× 120 0.9× 40 815
Sheng Yang China 16 149 0.3× 406 0.8× 196 0.8× 289 1.3× 192 1.4× 105 781
Joo Han Lim South Korea 18 335 0.7× 393 0.8× 144 0.6× 85 0.4× 69 0.5× 61 867
Ching-Liang Ho Taiwan 13 251 0.5× 475 1.0× 451 2.0× 93 0.4× 140 1.0× 27 923

Countries citing papers authored by Luca Paoluzzi

Since Specialization
Citations

This map shows the geographic impact of Luca Paoluzzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Paoluzzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Paoluzzi more than expected).

Fields of papers citing papers by Luca Paoluzzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Paoluzzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Paoluzzi. The network helps show where Luca Paoluzzi may publish in the future.

Co-authorship network of co-authors of Luca Paoluzzi

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Paoluzzi. A scholar is included among the top collaborators of Luca Paoluzzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Paoluzzi. Luca Paoluzzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Postovalova, Ekaterina, Meng Wang, Matthew Lee, et al.. (2025). Transcriptomic Profiling and Tumor Microenvironment Classification Reveal Unique and Dynamic Immune Biology in HIV-Associated Kaposi Sarcoma. Cells. 14(2). 134–134. 1 indexed citations
2.
Gabrail, Nashat, Miranda Gogishvili, Tamta Makharadze, et al.. (2024). A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8660–TPS8660. 2 indexed citations
3.
Melkadze, Tamar, Nashat Gabrail, Emad Ibrahim, et al.. (2024). A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.. Journal of Clinical Oncology. 42(16_suppl). TPS8663–TPS8663. 4 indexed citations
4.
Subbiah, Suki, Jessica Y. Islam, Cassandra Hennessy, et al.. (2022). COVID-19 outcomes in patients with cancer and HIV: An analysis of the COVID-19 and Cancer Consortium (CCC19).. Journal of Clinical Oncology. 40(16_suppl). e18790–e18790. 1 indexed citations
5.
Paoluzzi, Luca & Robert G. Maki. (2018). Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma. JAMA Oncology. 5(2). 254–254. 88 indexed citations
6.
Paoluzzi, Luca & Munir Ghesani. (2018). Extraskeletal myxoid chondrosarcoma with massive pulmonary metastases. SHILAP Revista de lepidopterología. 8(1). 20–20. 3 indexed citations
7.
Paoluzzi, Luca, Adrienne Cacavio, Munir Ghesani, et al.. (2016). Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. PubMed. 6(1). 24–24. 149 indexed citations
8.
Scotto, Luigi, Marianna Kruithof‐de Julio, Luca Paoluzzi, et al.. (2012). Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas. Clinical Cancer Research. 18(14). 3803–3811. 10 indexed citations
9.
Paoluzzi, Luca, Luigi Scotto, Enrica Marchi, et al.. (2010). Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma. Clinical Cancer Research. 16(2). 554–565. 58 indexed citations
10.
Marchi, Enrica, Luca Paoluzzi, Luigi Scotto, et al.. (2010). Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies. Clinical Cancer Research. 16(14). 3648–3658. 52 indexed citations
11.
12.
Montanari, Francesca, et al.. (2010). Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 10(5). E43–E46. 28 indexed citations
13.
Paoluzzi, Luca, Yukiko Kitagawa, Matko Kalac, Jasmine Zain, & Owen A. O’Connor. (2008). New Drugs for the Treatment of Lymphoma. Hematology/Oncology Clinics of North America. 22(5). 1007–1035. 7 indexed citations
14.
Moroni, Lorenzo, et al.. (2008). Regenerating Articular Tissue by Converging Technologies. PLoS ONE. 3(8). e3032–e3032. 23 indexed citations
15.
16.
17.
Paoluzzi, Luca, Arun S. Singh, Douglas K. Price, et al.. (2004). Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38. The Journal of Clinical Pharmacology. 44(8). 854–860. 86 indexed citations
18.
Paoluzzi, Luca & William D. Figg. (2004). Histone deacetylase inhibitors are potent radiation protectants. Cancer Biology & Therapy. 3(7). 612–613. 17 indexed citations
19.
Giorgi, Ugo De, Giovanni Rosti, Giorgio Papiani, et al.. (2004). Weekly Gemcitabine, Paclitaxel, Oxaliplatin Combination Chemotherapy in Patients With Cisplatin-Refractory Germ Cell Tumor. American Journal of Clinical Oncology. 27(5). 457–460. 15 indexed citations
20.
Marinis, Filippo de, Maria Rita Migliorino, Luca Paoluzzi, et al.. (2003). Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 39(3). 331–338. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lai‐Fa Sheu Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by Vijay Peddareddigari Breakdown of academic impact, for papers by Miyuki Akutsu Breakdown of academic impact, for papers by L. Austin Doyle Breakdown of academic impact, for papers by Rodney R. Miles Breakdown of academic impact, for papers by Masafumi Takimoto Breakdown of academic impact, for papers by Sheng Yang Breakdown of academic impact, for papers by Joo Han Lim Breakdown of academic impact, for papers by Ching-Liang Ho
Rankless by CCL
2026